<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1090">
  <stage>Registered</stage>
  <submitdate>28/02/2006</submitdate>
  <approvaldate>28/02/2006</approvaldate>
  <nctid>NCT00298194</nctid>
  <trial_identification>
    <studytitle>The Effects of Z-338 in Subjects With and Without Functional Dyspepsia</studytitle>
    <scientifictitle>The Effects of Z-338 on the Symptomatic Response to a Nutrient Challenge and Gastric Nutrient Distribution and Emptying in Subjects With and Without Functional Dyspepsia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>99010205E</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dyspepsia</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Z-338

Treatment: drugs: Z-338


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>1. Subjects with functional dyspepsia Positive documented diagnosis of FD via RomeII
             criteria and three or more moderate symptoms of Gastrointestinal Score

          2. Subjects with no history of functional dyspepsia Clinical assessment, physical
             examination and laboratory testing without evidence for relevant abnormality.

        Other protocol-defined inclusion/exclusion criteria may apply.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>52</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zeria Pharmaceutical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess in subjects with and without functional dyspepsia the effects of Z-338 on:

        1. Type and severity of symptoms a standardized nutrient challenge

        2. The gastric nutrient distribution and gastric emptying of a standardized nutrient
           challenge

        3. The association of the above with the manifestations of symptoms and symptom pattern</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00298194</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerald Holtmann, Professor</name>
      <address>Royal Adelaide Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>